When children fall ill, they deserve to receive treatments that are both safe and effective. Yet 50% of medicines used in children have never been tested in children. That figure rises to 90% for babies. Legislation on both sides of the Atlantic is boosting the testing of medicines in pediatric populations, yet challenges remain. For example, it is often hard to find enough young patients to carry out a clinical trial, so trials last longer and are more likely to stall. In this session, panelists will discuss initiatives in the US and Europe that are setting up large-scale collaborative pediatric clinical trial networks to improve the conduct of trials, facilitate the participation of children and promote novel trial designs.